<DOC>
	<DOCNO>NCT01161160</DOCNO>
	<brief_summary>This study design characterize safety immunogenicity pandemic influenza ( H1N1 ) candidate vaccine GSK2340274A GSK234072A child 3 less 10 year old .</brief_summary>
	<brief_title>Safety Immune Response Candidate H1N1 Influenza Vaccines GSK2340274A GSK234072A Children 3 Less Than 10 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male premenarchal female child 3 &lt; 10 year age time study vaccination . `` Less 10 year age '' implies inclusion child reach 10th birthday Day 0 , day study vaccine dose protocol . Written inform consent obtain subject 's parent/legally acceptable representative ( LAR ) ; write informed assent obtain subject appropriate . Good general health establish medical history clinical examination enter study . Subjects and/or parent ( ) /LAR investigator believe comply requirement protocol documented signature inform consent document ( , appropriate , inform assent document ) . Medical history physicianconfirmed infection A/California/7/2009 ( H1N1 ) vlike virus . Previous vaccination time A/California/7/2009 ( H1N1 ) vlike virus vaccine . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject parent ( ) / LAR ( ) unable/unlikely provide accurate safety report . Presence temperature ≥ 38.0ºC route method , acute symptom great `` mild '' severity schedule date vaccination . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Receipt systemic glucocorticoid within 1 month prior study enrollment ( day study vaccination ) , cytotoxic immunosuppressive drug within 6 month study enrollment . Topical , intraarticular inhale glucocorticoid allow . Receipt immunoglobulins and/or blood product within 6 month study enrollment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin eligible dos give 24 hour study vaccination . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible . Administration license liveattenuated vaccine within 30 day study vaccination license inactivated vaccine within 15 day study vaccination . Planned administration A/California H1N1vlike vaccine study vaccine Day 0 Day 21 phlebotomy . Planned administration vaccine foreseen study protocol Day 0 Day 21 . Routine childhood vaccination exempt delayed , must administer day H1N1 vaccine candidate . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede study vaccination , plan use study period . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Child care ( A child place control protection agency , organization , institution entity court ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>H1N1</keyword>
	<keyword>Influenza</keyword>
	<keyword>Pandemic</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340274A GSK234072A</keyword>
</DOC>